A Study of LY3009104(Baricitinib) for Healthy Subjects

Phase 1

Completed

• Conditions: Healthy Volunteer
• Interventions: Drug: LY3009104; Drug: Placebo

• Registration Number: NCT01247350
• Lead Sponsor: Eli Lilly and Company

Brief Summary

To evaluate the safety and tolerability of LY3009104 when given orally as single and multiple doses in Japanese healthy subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2010-11-17
• Study First Submitted QC: 2010-11-22
• Study First Posted: 2010-11-24
• Primary Completion: 2011-04
• Study Completion: 2011-04
• Results First Submitted: 2017-03-10
• Status Verified: 2017-09
• Results First Submitted QC: 2017-09-06
• Last Update Submitted: 2017-09-06
• Results First Posted: 2018-04-13
• Last Update Posted: 2018-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

• Healthy males or females. Male subjects: Agree to use 2 forms of highly effective methods of birth control with female partners of childbearing potential for the specified duration. Female subjects: Females must not be pregnant, breastfeeding, or at risk to become pregnant during study participation. Female subjects of childbearing potential must test negative for pregnancy at screening and agree to use 2 forms of highly effective methods of birth control, or remain abstinent for the specified duration.
• Up to third generation Japanese, that is defined as all of the subject's biological grandparents are of exclusive Japanese decent and have been born in Japan.
• Are between the body mass index (BMI) of 18.0 and 30.0 kg/m², inclusive at screening.

Read More

Exclusion Criteria

• Are subjects who have previously completed or withdrawn from this study or any other study investigating LY3009104, and received the study drug.
• Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
• Show evidence of significant active neuropsychiatric disease.
• Have current or recent history of herpes zoster or simplex in the last 90 days prior to randomization, or history of herpes zoster, such as disseminated herpes zoster involving multiple dermatomes, ocular involvement, including herpes zoster involving the ophthalmic branch of the trigeminal nerve.
• Have or have a history of rheumatoid arthritis.
• History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin.
• History of stomach or intestinal surgery, except that appendectomy and/or cholecystectomy will be allowed.
• Receipt of blood products within 2 months prior to study entry.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
10 mg LY3009104 (Cohort 3)	LY3009104	10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
2 mg LY3009104 (Cohort 1)	LY3009104	2mg administered once on day 1 (single dose)
5 mg LY3009104 (Cohort 2)	LY3009104	5mg administered once on day 1 (single dose)
14 mg LY3009104 (Cohort 4 )	LY3009104	14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
Placebo	Placebo	administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)

Primary Outcome Measures

Name	Time	Method
Number of Participants With Clinically Significant Effects	Days 1-10 for Cohorts 1 & 2, Days 1-7 for single dose of Cohorts 3 & 4, Days 8-31 for multiple doses	Adverse events were considered clinically significant effects. A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104	Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose	Cmax of Day 1 is Cmax after single dose, and Cmax of Day 17 is Cmax at steady-state.
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104	Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose	AUC is the measure of total plasma exposure of a drug over a given time period. AUC of Day 1 is AUC from 0 to 24 hours. AUC of Day 17 is AUC during one dosing interval at steady-state.
Pharmacokinetics: Half-Life(t1/2) of LY3009104	Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose	Half life (t1/2) is the time measured for the plasma concentration of LY3009104 to decrease by one half.
Pharmacokinetics: Apparent Total Body Clearance of LY3009104	Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose	Apparent total body clearance is the volume of plasma from which the drug is completely removed in a given time period. For Day 1, it is apparent total body clearance of drug after single dose. For Day 17, it is apparent total body clearance of drug at steady-state.
Pharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax)	Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose	Tmax is time to reach maximum observed drug concentration. For Day 1, it is tmax after single dose. For Day 17, it is tmax at steady-state.
Pharmacokinetics: Renal Excretion of LY3009104	Day 1: continuous for 24 hours	Percentage of LY3009104 excreted in urine from zero to 24 hours.
Pharmacokinetics: Apparent Volume of Distribution of LY3009104	Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose	Apparent volume of distribution is used to quantify the distribution of a drug between plasma and the rest of the body after dosing. It is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Day 1, it is apparent volume of distribution during the terminal phase after single dose. Day 17, it is apparent volume of distribution during the terminal phase at steady-state.

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.; 🇺🇸 Honolulu, Hawaii, United States